The State of Weight-Loss Drugs
$150 billion. That’s how much some experts estimate weight-loss drugs could bring in in sales within the next five years. Motley Fool analyst Karl Thiel joins Ricky Mulvey to check in on the GLP-1 landscape. They also discuss: - How weight-loss drugs actually work, and how big-name prescriptions differ from each…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from Motley Fool Hidden Gems Investing
See all episodes →Similar episodes from other shows
More like Motley Fool Hidden Gems Investing →
Here's How the New Weight Loss Drugs Could Change Everything
What the Expanding Reach of Weight-Loss Drugs Means For Health Care 10/11/23
Novo Nordisk, Eli Lilly and the GLP-1 economy
Can a GLP-1 Pill Revive Novo Nordisk?
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.